Ronald van Toorn1, H Simon Schaaf, Jacoba A Laubscher, Sabine L van Elsland, Peter R Donald, Johan F Schoeman. 1. From the *Department of Pediatrics and Child Health, Stellenbosch University and Tygerberg Children's Hospital, Western Cape; †Biostatistics Unit, Medical Research Council of South Africa, Tygerberg, Cape Town, South Africa; and ‡Department of Pediatric Infectious Diseases and Immunology, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND: The World Health Organization recommends 12-month treatment (2RHZE/10RH) for children with tuberculous meningitis (TBM). Studies evaluating length of antituberculous treatment for TBM report similar completion and relapse rates comparing 6-month treatment with 12-month treatment. METHODS: A prospective evaluation to determine whether short-course intensified treatment (6 RHZEth for HIV-infected and 9RHZEth for HIV-infected) is sufficient and safe in children with drug-susceptible TBM. RESULTS: Of 184 children with TBM, median age 58 months and 90 (49%) male, 98 children (53%) presented at stage II TBM, 64 (35%) at stage III TBM and only 22 (12%) at stage I TBM. Ninety (49%) children were treated at home after the first month of therapy; all others received their full treatment in hospital. The HIV prevalence was 14% (22/155 children tested). Anti-TB drug-induced hepatotoxicity occurred in 5% (8 of 143 children tested), all tested negative for viral hepatitis; in all 8 cases, the original regimen was restarted without recurrence. After treatment completion, 147 (80%) children had a good outcome, 7 (3.8%) died. There was no difference in outcome between HIV-infected and HIV-uninfected children who completed treatment (P = 0.986) nor between TBM-hydrocephalic children who were medically treated or shunted (P = 0.166). CONCLUSION: Short intensified treatment is safe and effective in both HIV-infected and HIV-uninfected children with drug-susceptible TBM.
BACKGROUND: The World Health Organization recommends 12-month treatment (2RHZE/10RH) for children with tuberculous meningitis (TBM). Studies evaluating length of antituberculous treatment for TBM report similar completion and relapse rates comparing 6-month treatment with 12-month treatment. METHODS: A prospective evaluation to determine whether short-course intensified treatment (6 RHZEth for HIV-infected and 9RHZEth for HIV-infected) is sufficient and safe in children with drug-susceptible TBM. RESULTS: Of 184 children with TBM, median age 58 months and 90 (49%) male, 98 children (53%) presented at stage II TBM, 64 (35%) at stage III TBM and only 22 (12%) at stage I TBM. Ninety (49%) children were treated at home after the first month of therapy; all others received their full treatment in hospital. The HIV prevalence was 14% (22/155 children tested). Anti-TB drug-induced hepatotoxicity occurred in 5% (8 of 143 children tested), all tested negative for viral hepatitis; in all 8 cases, the original regimen was restarted without recurrence. After treatment completion, 147 (80%) children had a good outcome, 7 (3.8%) died. There was no difference in outcome between HIV-infected and HIV-uninfectedchildren who completed treatment (P = 0.986) nor between TBM-hydrocephalic children who were medically treated or shunted (P = 0.166). CONCLUSION: Short intensified treatment is safe and effective in both HIV-infected and HIV-uninfectedchildren with drug-susceptible TBM.
Authors: L M van Leeuwen; P Versteegen; S D Zaharie; S L van Elsland; A Jordaan; E M Streicher; R M Warren; M van der Kuip; A M van Furth Journal: J Clin Microbiol Date: 2019-07-26 Impact factor: 5.948
Authors: Anna Turkova; James A Seddon; Andrew J Nunn; Diana M Gibb; Patrick P J Phillips Journal: Pediatr Infect Dis J Date: 2014-09 Impact factor: 2.129
Authors: Angharad G Davis; Sean Wasserman; Mpumi Maxebengula; Cari Stek; Marise Bremer; Remy Daroowala; Saalikha Aziz; Rene Goliath; Stephani Stegmann; Sonya Koekemoer; Amanda Jackson; Louise Lai Sai; Yakub Kadernani; Thandi Sihoyiya; C Jason Liang; Lori Dodd; Paolo Denti; Thomas Crede; Jonathan Naude; Patryk Szymanski; Yakoob Vallie; Ismail Banderker; Shiraz Moosa; Peter Raubenheimer; Rachel P J Lai; John Joska; Sam Nightingale; Anna Dreyer; Gerda Wahl; Curtis Offiah; Isak Vorster; Sally Candy; Frances Robertson; Ernesta Meintjes; Gary Maartens; John Black; Graeme Meintjes; Robert J Wilkinson Journal: Wellcome Open Res Date: 2021-06-01
Authors: Ursula K Rohlwink; Kirsty Donald; Bronwyn Gavine; Llewellyn Padayachy; Jo M Wilmshurst; Graham A Fieggen; Anthony A Figaji Journal: Dev Med Child Neurol Date: 2016-02-16 Impact factor: 5.449
Authors: Thomas Pouplin; Nguyen Duc Bang; Pham Van Toi; Pham Nguyen Phuong; Nguyen Huy Dung; Tran Ngoc Duong; Maxine Caws; Guy E Thwaites; Joel Tarning; Jeremy N Day Journal: BMC Infect Dis Date: 2016-04-02 Impact factor: 3.090